Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent
IB 2019-01
Phase 2 small_molecule active
Quick answer
Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent for Adult participants with metastatic (advanced) solid tumors. is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Adult participants with metastatic (advanced) solid tumors.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active